US 12234230
Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
granted A61PA61P35/00A61P37/00
Quick answer
US patent 12234230 (Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof) held by NURIX THERAPEUTICS, INC. expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- NURIX THERAPEUTICS, INC.
- Grant date
- Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61P, A61P35/00, A61P37/00